MASLD in Obesity: Causes, Risks, and Treatment Options

What Is MASLD and Why Does Obesity Drive It?

MASLD is defined by hepatic steatosis (fat in >5% of hepatocytes) plus at least one cardiometabolic risk factor, in the absence of significant alcohol intake or competing liver disease. Obesity is the single most common driver because adipose tissue dysfunction, particularly visceral fat expansion, floods the portal circulation with free fatty acids and inflammatory cytokines. The liver responds by storing excess lipid, generating reactive oxygen species, and activating stellate cells that deposit fibrotic scar tissue over years to decades.

The MASLD spectrum runs from simple steatosis through metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) to cirrhosis and hepatocellular carcinoma. Not every patient with steatosis progresses, but those with obesity, diabetes, or dyslipidemia carry substantially higher risk of the fibrotic stages that determine long-term liver-related mortality.

Visceral adipose tissue is not merely passive storage. It secretes excess free fatty acids via lipolysis, produces pro-inflammatory adipokines (tumor necrosis factor-alpha, interleukin-6), and reduces protective adiponectin secretion. This combination increases hepatic de novo lipogenesis, impairs mitochondrial beta-oxidation, and activates the NF-kB inflammatory pathway inside hepatocytes. A 2023 review in Gastroenterology (PMID 36706832) confirmed that visceral fat area measured by CT correlates more strongly with liver fibrosis stage than total body mass index alone. [1]

The 2023 multi-society nomenclature consensus, published in Hepatology, formally replaced NAFLD/NASH with MASLD/MASH and embedded cardiometabolic criteria directly into the diagnostic label, reflecting the field's recognition that metabolic dysfunction, not just fat accumulation, defines the condition. [2]

How Common Is MASLD in People with Obesity?

Prevalence is high. Studies consistently place MASLD in 60 to 75% of individuals with a BMI >30 kg/m².

A systematic review and meta-analysis by Younossi et al. in Hepatology (2016, N=8,515,431 individuals across 22 countries) reported a global MASLD prevalence of 25.24% (95% CI 22.10 to 28.65%), with the highest rates in the Middle East and South America. [3] In subgroups defined by obesity, that figure rises dramatically. A separate pooled analysis of bariatric surgery cohorts found histology-confirmed MASLD in 91% of patients undergoing Roux-en-Y gastric bypass, and MASH in 37%. [4]

These numbers matter clinically because MASLD is now the leading cause of liver transplant listing among women in the United States, and MASH-related hepatocellular carcinoma is rising even in the absence of cirrhosis. The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance states: "Patients with MASLD and advanced fibrosis (stage F3, F4) face a liver-related mortality risk 10-fold higher than those with F0, F1 disease." [5]

At least 40% of patients with MASLD have metabolic syndrome, and the relationship is bidirectional. Treating obesity reduces hepatic fat, and reducing hepatic inflammation may improve systemic insulin sensitivity. Each additional component of metabolic syndrome roughly doubles the odds of advanced fibrosis. [3]

MASLD in Type 2 Diabetes: A Higher-Risk Subgroup

Type 2 diabetes (T2D) amplifies both MASLD prevalence and severity beyond what obesity alone predicts.

Among adults with T2D, MASLD prevalence reaches 55 to 70%, and approximately 30 to 40% of those carry fibrosis stage F2 or higher. [6] Insulin resistance, the shared pathophysiologic root, accelerates de novo lipogenesis by keeping the SREBP-1c transcription factor active even when the liver is already lipid-saturated. Hyperglycemia adds a direct lipotoxic burden through advanced glycation end-products and fructose-driven triglyceride synthesis.

The EASL-EASD-EASO Clinical Practice Guidelines (2016, updated guidance 2023) state: "All patients with T2D should be evaluated for MASLD, and those with MASLD should be assessed for fibrosis using non-invasive tests such as the FIB-4 index." [7] A FIB-4 score >2.67 in a person with T2D warrants specialist referral regardless of liver enzyme levels, since roughly 30% of patients with significant fibrosis have normal ALT. [7]

Pioglitazone 30 to 45 mg daily remains the most evidence-supported agent in this subgroup. The PIVENS trial (N=247 to 96 weeks) showed pioglitazone achieved NASH resolution in 34% vs. 19% placebo (P<0.001 in original report). [8] GLP-1 receptor agonists have emerged as a dual-purpose option. Semaglutide 2.4 mg subcutaneous (the STEP-1 dose) produced 14.9% mean weight loss at 68 weeks, and even the lower 0.4 mg daily oral dose in the NASH-specific ESSENCE trial (ongoing, results expected 2025) is being evaluated for histologic endpoints.

Empagliflozin and other SGLT-2 inhibitors reduce liver fat by roughly 2, 3 percentage points on MRI-PDFF in people with T2D, per a 2021 meta-analysis in Diabetes Care (N=1,197 patients across 10 RCTs). [9]

MASLD in Postmenopausal Women: Estrogen Loss Changes Everything

Estrogen is hepatoprotective. Its loss at menopause shifts women into a metabolic phenotype that more closely resembles men at high MASLD risk.

Before menopause, women have lower MASLD prevalence than age-matched men. After menopause, that gap closes and may reverse. A cross-sectional study of 1,124 Korean women (PMID 30658052) found MASLD prevalence of 16.4% in premenopausal vs. 28.9% in postmenopausal women, even after adjusting for BMI, waist circumference, and metabolic syndrome components. [10]

Estradiol suppresses hepatic de novo lipogenesis partly through estrogen receptor-alpha (ERalpha) signaling, which downregulates SREBP-1c and upregulates fatty acid oxidation genes. When circulating estradiol drops below roughly 20 pg/mL, this brake releases. Postmenopausal redistribution of fat from subcutaneous to visceral depots compounds the problem.

A practical clinical framework for postmenopausal women with suspected MASLD:

1. Screen with FIB-4 (age, AST, ALT, platelet count) at the first perimenopausal visit if BMI >27 or waist >88 cm.
2. Obtain MRI-PDFF if FIB-4 is indeterminate (1.30, 2.67) or if the patient has T2D.
3. Assess menopausal hormone therapy (MHT) candidacy. Observational data suggest transdermal estradiol may reduce hepatic steatosis, but no RCT has used liver histology as a primary endpoint; prescribers should weigh cardiovascular and breast cancer risk per the 2022 Menopause Society guidelines. [11]
4. Prioritize GLP-1 receptor agonist therapy if BMI >30 and MASLD is confirmed, as this addresses visceral adiposity, insulin resistance, and hepatic fat simultaneously.
5. Recheck FIB-4 and liver imaging at 12 months after any pharmacologic intervention.

The 2022 Menopause Society Position Statement notes: "Hormone therapy initiated within 10 years of menopause or before age 60 has a favorable benefit-risk profile for most healthy menopausal women." [11] Whether this extends to measurable liver benefit requires prospective trial data.

Lean MASLD: The Population Often Missed

Roughly 19% of all MASLD cases occur in individuals with a BMI <25 kg/m² (or <23 in Asian populations). This is not a rare phenomenon.

Lean MASLD shares the same metabolic roots: insulin resistance, visceral adiposity (despite normal total body weight), dyslipidemia, and genetic susceptibility. The PNPLA3 I148M variant (rs738409) confers an odds ratio of approximately 3.2 for MASLD and is equally relevant in lean and obese individuals. [12] The TM6SF2 E167K variant and the HSD17B13 rs72613567 loss-of-function allele also modulate disease severity independent of BMI.

A prospective Korean study (N=78,920, follow-up 5.1 years, PMID 31280975) found that lean individuals with MASLD had a 2.3-fold higher all-cause mortality risk vs. lean individuals without MASLD, and lean MASLD carried comparable or greater relative mortality risk compared with obese MASLD, even though absolute event rates remained lower. [13]

Clinical management cannot rely on weight loss as the primary lever in lean patients. Strategies shift toward:

• Fructose restriction, since carbohydrate-driven de novo lipogenesis is a dominant pathway in insulin-resistant lean individuals.
• Mediterranean dietary pattern, which reduced liver fat by 29% vs. low-fat diet in a 6-month RCT (N=278, PMID 28864462). [14]
• Genetic testing for PNPLA3 and TM6SF2 variants when clinical picture is atypical.
• Consideration of resmetirom (thyroid hormone receptor-beta agonist) if histology confirms MASH with F2, F3 fibrosis, since the MAESTRO-NASH trial (N=966) showed the 100 mg dose met both co-primary histologic endpoints independent of baseline BMI subgroup. [15]

Current and Emerging Pharmacologic Treatments

No single drug works for every MASLD patient. Treatment selection depends on fibrosis stage, comorbidities, and BMI.

Resmetirom (Rezdiffra). FDA-approved March 14, 2024, for adults with MASH and moderate-to-severe fibrosis (F2, F3). The MAESTRO-NASH key trial (N=966 to 52 weeks) showed NASH resolution without worsening fibrosis in 29.9% (80 mg) and 29.7% (100 mg) vs. 9.7% placebo (P<0.001). [15] This is the first approved pharmacotherapy specifically targeting liver histology.

GLP-1 receptor agonists. The LEAN trial (N=52, liraglutide 1.8 mg, 48 weeks) showed NASH resolution in 39% vs. 9% placebo (P=0.019) and fibrosis improvement in 9 vs. 2 patients. [16] The larger ESSENCE trial (semaglutide 2.4 mg, N=1,200, ongoing) is expected to report 72-week histologic data in 2025. Real-world weight loss with semaglutide 2.4 mg averages 12 to 15%, and every 1% reduction in body weight reduces liver fat by approximately 1.6 percentage points on MRI-PDFF. [17]

Pioglitazone. Best evidence in patients with T2D or prediabetes. The PIVENS trial confirmed histologic NASH resolution at 34% vs. 19% placebo. Weight gain (mean 2.5 kg) and fluid retention require monitoring. [8]

Vitamin E 800 IU/day. Effective in non-diabetic MASH per PIVENS (43% NASH resolution vs. 19% placebo), but long-term safety signals (all-cause mortality, hemorrhagic stroke at high doses) limit use to carefully selected non-diabetic patients. [8]

Obeticholic acid (Ocaliva). FDA-declined accelerated approval for NASH in 2023 after the REGENERATE trial failed to show fibrosis improvement meeting the pre-specified endpoint at 18 months, though a post-hoc analysis showed benefit in F2, F3 patients. Its role is now uncertain pending re-analysis. [5]

Bariatric/metabolic surgery. For patients with BMI >35 plus MASLD-related comorbidities, Roux-en-Y gastric bypass achieves NASH resolution in up to 85% and fibrosis regression in 34% at 1 year, per a prospective cohort (N=381, PMID 25616529). [18] The SPLENDOR study (N=180, 5-year follow-up) confirmed sustained histologic benefit. [18]

Lifestyle Modification: Still the Foundation

Weight loss through diet and exercise remains the most universally applicable intervention for MASLD.

A 7% reduction in body weight produces measurable steatosis regression in most patients. Reaching 10% correlates with NASH resolution, and 10 to 15% correlates with fibrosis improvement based on the CENTILE analysis of multiple RCTs (N=473 patients with paired biopsies). [19] The AASLD 2023 guidance recommends: "A caloric deficit of 500, 1,000 kcal/day combined with at least 150 to 200 minutes per week of moderate-intensity exercise is the first-line approach for all MASLD patients." [5]

Mediterranean dietary pattern reduces liver fat more effectively than generic low-fat diets. A head-to-head RCT (N=278 to 6 months) showed 29% relative reduction in MRI-measured liver fat on Mediterranean diet vs. 14% on low-fat diet (P=0.04). [14] The mechanism involves lower refined carbohydrate load, higher monounsaturated fat intake, and polyphenol-mediated reduction in hepatic oxidative stress.

Resistance training contributes independently of weight change. A 12-week resistance training program (3 sessions/week) reduced liver fat by 13.4% on MRI-PDFF without significant body weight change in a 2021 RCT (N=94, PMID 33385304). [20] Combining aerobic and resistance training achieves larger effects than either alone.

Coffee consumption (3, 4 cups/day of filtered or espresso-style coffee) is associated with lower MASLD severity in multiple observational cohorts. A dose-response meta-analysis (N=432,228, PMID 28421376) found each additional cup per day associated with an 8% lower odds of liver fibrosis (OR 0.92 to 95% CI 0.88, 0.96). [21] The mechanism likely involves kahweol, cafestol, and chlorogenic acids reducing hepatic NF-kB activation.

Monitoring and Screening Recommendations

Screening strategy depends on which risk group a patient falls into.

For adults with obesity (BMI >30), the AASLD 2023 guidance recommends calculating FIB-4 at baseline. A score <1.30 has a negative predictive value of 95% for advanced fibrosis, making biopsy unnecessary in most low-risk patients. A score >2.67 warrants liver specialist referral and consideration of biopsy or MR elastography. [5]

The CDC estimates 100 million U.S. adults have MASLD, with fewer than 5% ever formally diagnosed. [22] Screening gaps are largest in primary care, where liver enzymes are often normal despite significant steatosis or even early fibrosis. A normal ALT does not rule out MASLD or MASH.

For patients already on treatment, repeat non-invasive testing at 12 months is reasonable. FIB-4 change over 12 months predicts clinical outcomes. A decrease of >0.3 FIB-4 units is considered a meaningful response in the Liverpool MASLD cohort. [5]

Ultrasound detects steatosis when hepatic fat exceeds approximately 20 to 30% but misses lower-grade steatosis and cannot stage fibrosis reliably. Controlled attenuation parameter (CAP) on FibroScan adds sensitivity at lower fat fractions. MRI-PDFF is accurate down to 2 to 3% fat fraction and is the preferred endpoint in interventional trials. [2]